Jan Berger, MD, MJ, President & CEO, Health Intelligence Partners, Editor-in-Chief, The American Journal of Pharmacy Benefits, says although Pharmacy Benefit Management (PBM) is becoming more sophisticated, providers are working to reduce confusion about benefit tier explanations.
Jan Berger, MD, MJ, President & CEO, Health Intelligence Partners, Editor-in-Chief, The American Journal of Pharmacy Benefits, says although Pharmacy Benefit Management (PBM) is becoming more sophisticated, providers are working to reduce confusion about benefit tier explanations. By pharmacy and healthcare companies increasingly collaborating, benefits will likely become more holistic.
Dr Berger says that pharmacy and medical benefit integration is “truly a win-win” situation, as it will create better outcomes for both members and costs.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More